Literature DB >> 27867637

Harnessing plasma genotyping for precision therapy against lung cancer.

Xiang Yan1, Bingliang Fang2.   

Abstract

Entities:  

Year:  2016        PMID： 27867637      PMCID： PMC5107466          DOI： 10.21037/jtd.2016.10.95

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  24 in total

1.  Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Authors:  Masahiro Fukuoka; Yi-Long Wu; Sumitra Thongprasert; Patrapim Sunpaweravong; Swan-Swan Leong; Virote Sriuranpong; Tsu-Yi Chao; Kazuhiko Nakagawa; Da-Tong Chu; Nagahiro Saijo; Emma L Duffield; Yuri Rukazenkov; Georgina Speake; Haiyi Jiang; Alison A Armour; Ka-Fai To; James Chih-Hsin Yang; Tony S K Mok
Journal:  J Clin Oncol       Date:  2011-06-13       Impact factor: 44.544

2.  U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.

Authors:  Sean Khozin; Gideon M Blumenthal; Xiaoping Jiang; Kun He; Karen Boyd; Anthony Murgo; Robert Justice; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2014-05-27

3.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.

Authors:  Antonio Marchetti; Carla Martella; Lara Felicioni; Fabio Barassi; Simona Salvatore; Antonio Chella; Pier P Camplese; Teodorico Iarussi; Felice Mucilli; Andrea Mezzetti; Franco Cuccurullo; Rocco Sacco; Fiamma Buttitta
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

Review 4.  Bronchoalveolar lavage and lung biopsy in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review and meta-analysis.

Authors:  DeepakBabu Chellapandian; Thomas Lehrnbecher; Bob Phillips; Brian T Fisher; Theoklis E Zaoutis; William J Steinbach; Joseph Beyene; Lillian Sung
Journal:  J Clin Oncol       Date:  2015-01-05       Impact factor: 44.544

Review 5.  Tumour seeding following percutaneous needle biopsy: the real story!

Authors:  E G Robertson; G Baxter
Journal:  Clin Radiol       Date:  2011-07-23       Impact factor: 2.350

Review 6.  Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

Authors:  Lecia V Sequist; Daphne W Bell; Thomas J Lynch; Daniel A Haber
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

7.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.

Authors:  Jianjun Zhang; Junya Fujimoto; Jianhua Zhang; David C Wedge; Xingzhi Song; Jiexin Zhang; Sahil Seth; Chi-Wan Chow; Yu Cao; Curtis Gumbs; Kathryn A Gold; Neda Kalhor; Latasha Little; Harshad Mahadeshwar; Cesar Moran; Alexei Protopopov; Huandong Sun; Jiabin Tang; Xifeng Wu; Yuanqing Ye; William N William; J Jack Lee; John V Heymach; Waun Ki Hong; Stephen Swisher; Ignacio I Wistuba; P Andrew Futreal
Journal:  Science       Date:  2014-10-10       Impact factor: 47.728

8.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Authors:  Geoffrey R Oxnard; Kenneth S Thress; Ryan S Alden; Rachael Lawrance; Cloud P Paweletz; Mireille Cantarini; James Chih-Hsin Yang; J Carl Barrett; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

9.  EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.

Authors:  Kenneth S Thress; Roz Brant; T Hedley Carr; Simon Dearden; Suzanne Jenkins; Helen Brown; Tracey Hammett; Mireille Cantarini; J Carl Barrett
Journal:  Lung Cancer       Date:  2015-10-09       Impact factor: 5.705

10.  EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital.

Authors:  Yoon-La Choi; Jong-Mu Sun; Juhee Cho; Sanjay Rampal; Joungho Han; Bhash Parasuraman; Eliseo Guallar; Genehee Lee; Jeeyun Lee; Young Mog Shim
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.